biologic

Varizig

Varicella Zoster Immune Globulin (Human)

Loss of exclusivitySeptember 2026projected — 12-year biologic exclusivity estimate
CompanyKamada Ltd.View the full company profile on CliffBio

Drug detail

Brand nameVarizig
Active ingredientVaricella Zoster Immune Globulin (Human)
Strength125IU
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalSeptember 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Varizig patent cliff — loss of exclusivity September 2026 | CliffBio